OPKO Health, Inc. OPK Cash Flow

Opko health, inc. (OPK)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
-293,295	-314,925	-278,646	-244,293	-190,688	-153,040	-294,883	-303,146	-313,861	-305,250	-124,272	-103,332	-70,884	-48,359	-9,820	133,404	74,631	-31,428	-86,493	-264,753	-247,584	-174,638	-138,606	-149,394	-127,675	-117,346	-100,956	-49,801	-55,691	-29,540	-10,097	-8,687	-4,190	-1,283	0	0	0
Income from discontinued operations, net of tax
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,181	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
92,043	93,807	95,185	95,303	96,403	97,344	98,856	100,330	101,120	102,093	100,641	101,077	100,107	96,576	94,787	81,343	60,922	42,248	23,731	15,021	14,888	14,927	15,837	15,927	15,351	15,216	13,361	12,258	11,261	10,160	8,419	6,794	5,289	3,830	0	0	0
Non-cash interest
8,204	8,731	5,902	5,573	7,070	4,903	4,190	3,479	2,778	2,575	2,580	2,585	2,590	2,699	2,499	2,339	2,305	2,612	3,242	3,786	4,941	5,662	6,326	6,417	6,454	5,980	0	0	0	-	-	-	-	-	-	-	-
Amortization of Debt Issuance Costs
793	995	538	396	549	187	211	211	211	224	230	275	256	237	212	391	498	1,212	1,275	1,095	2,581	2,007	2,084	2,634	1,202	1,170	0	0	0	-	-	-	-	-	-	-	-
Income (Loss) from Equity Method Investments
0	-	0	0	0	-	0	0	-14,796	-	-14,276	-11,077	-7,438	-7,652	-6,185	-8,873	-7,689	-7,105	-7,168	-3,726	-3,292	-3,587	-6,081	-7,621	-9,622	-11,456	-8,459	-7,327	-5,429	-2,062	-1,878	-1,711	-1,689	-1,589	0	0	0
Accretion of debt discount related to notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Equity-based compensation – employees and non-employees
11,394	13,400	16,216	17,865	20,321	21,800	22,599	23,970	24,543	28,300	30,053	32,439	35,086	42,700	43,248	38,089	35,981	26,074	22,456	21,876	18,600	14,779	13,660	10,973	9,357	10,983	9,261	9,965	9,156	5,131	4,884	5,554	6,487	6,953	0	0	0
Realized loss on disposal of fixed assets and sales of equity securities
0	-	-	-	0	-	-	-	-	-	-	-	-	-2,321	-8,250	-4,813	-7,307	-7,091	-1,224	-1,225	-1,224	-167	20,201	20,334	28,807	29,881	0	0	0	-	-	-	-	-	-	-	-
Provision for bad debts
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	149	582	524	979	704	325	437	-95	8	-53	123	257	0	0	0
Provision for inventory obsolescence
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,259	1,325	1,413	2,015	2,697	3,207	3,372	2,688	1,593	1,045	914	607	0	0	0
Revenue from receipt of equity
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	140	200	240	240	240	240	240	260	12,740	12,680	12,677	12,648	159	0	0	0	-	-	-	-
Loss (gain) on conversion of 3.00% convertible senior notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	943	943	-291	2,347	2,668	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Loss (gain) on disposal of fixed assets
-	-	-	-	-	-	-	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of equity securities and derivative instruments
-19,832	-8,748	-25,000	-13,726	5,248	6,524	12,429	5,352	-884	52	10,636	12,485	8,238	2,778	-10,872	27,073	9,282	-39,083	-48,490	-77,570	-50,047	-10,632	-3,493	-34,450	-32,766	-45,942	-38,782	-10,820	-23,448	1,218	0	0	0	-	-	-	-
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability
-20,520	-14,854	-4,488	-2,186	-13,769	-16,816	-11,354	-23,760	-4,035	-3,423	-3,125	11,181	17,572	16,954	14,183	12,725	1,628	5,050	6,839	24,796	27,011	24,446	26,852	7,512	8,213	6,947	2,293	2,597	985	785	0	0	0	-	-	-	-
Asset Impairment Charges
91,745	92,400	22,433	22,433	22,433	21,778	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred income tax (benefit) provision
5,289	4,324	-18,527	-32,939	-32,776	-35,133	47,917	37,105	22,619	16,092	-81,684	-80,340	-53,292	-66,300	-57,805	-132,535	-145,780	-123,536	0	0	0	-	-	-	-	599	0	0	0	-	-	-	-	-	-	-	-
Changes in assets and liabilities, net of the effects of acquisitions:
Accounts receivable, net
-7,052	-7,376	-15,953	-3,559	-13,201	-20,397	-79,306	-101,316	-82,539	-58,011	10,257	38,114	33,484	25,637	28,115	19,047	14,840	4,845	4,837	3,138	2,645	3,273	2,662	1,915	-755	-754	-223	-1,792	-2,896	-763	-620	2,464	3,887	1,719	0	0	0
Inventory, net
18,489	12,133	9,010	2,529	-1,911	-4,590	1,211	2,202	3,285	3,539	2,152	5,287	6,505	6,607	1,955	4,169	2,715	4,953	5,295	1,804	1,384	670	159	734	-1,655	-1,892	412	1,273	2,813	5,807	6,353	4,985	3,945	-2,170	0	0	0
Other current assets and prepaid expenses
12,169	11,486	-4,024	-8,482	3,215	-2,276	-3,324	2,651	-5,524	-4,771	-38,715	-35,263	-28,837	-17,262	24,476	19,842	12,218	4,391	4,530	-858	-2,839	-3,182	-4,437	-4,907	-2,726	1,131	3,646	4,131	4,966	2,877	1,479	1,280	315	-57	0	0	0
Other assets
-712	-409	-4,804	-213	181	69	6,556	2,264	2,268	2,372	1,946	2,885	3,581	1,899	1,969	-939	-1,651	305	6,581	7,801	5,316	3,378	-3,396	-3,270	-814	544	-87	275	297	361	-40	-9	57	-16	0	0	0
Accounts payable
7,058	15,636	13,843	-5,104	-12,164	-26,083	-1,171	2,640	-9,574	20,171	8,335	2,825	69	-19,819	1,241	-38,428	-20,578	-18,122	-35,506	6,557	-3,224	-3,852	-4,324	-1,812	3,411	1,829	3,881	2,376	1,415	1,247	1,537	1,132	94	-1,784	0	0	0
Foreign currency measurement
8	-71	384	502	282	294	-806	-562	-197	-255	665	259	-192	-376	-230	274	253	979	2,729	421	442	945	-4,803	-1,112	-1,750	-2,386	1,119	-427	712	-86	0	0	0	-	-	-	-
Contract liabilities
-60,680	-69,302	-67,593	-67,467	-63,979	-61,264	-59,636	-58,566	-88,083	-58,876	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-74,847	-72,193	-72,376	227,671	246,262	264,772	282,284	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses and other liabilities
-7,638	764	6,036	19,630	22,794	1,715	37,774	18,458	37,636	30,441	20,129	30,747	38,886	68,036	8,729	40,213	18,215	9,502	43,388	10,492	10,873	4,934	-5,069	-6,422	2,439	3,525	8,147	8,895	-15	1,678	-414	690	1,572	-21	0	0	0
Cash used in operating activities of continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-26,008	-25,742	-22,414	-13,939	0	0	0
Cash provided by operating activities of discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-267	-1,952	-2,900	-4,561	0	0	0
Net cash used in operating activities
-166,904	-172,522	-161,144	-159,161	-122,609	-109,141	-72,372	-88,096	-93,681	-92,080	-63,884	-58,173	7,333	32,046	-7,611	-7,078	-83,975	164,024	148,614	158,900	171,025	-90,379	-89,129	-82,063	-63,519	-55,653	-37,870	-25,786	-28,661	-25,415	-26,275	-27,694	-25,314	-18,500	0	0	0
Cash flows from investing activities:
Investments in investees
0	1,200	1,200	1,200	1,200	1,000	6,000	7,625	10,625	9,625	9,878	11,503	14,174	14,424	10,546	7,951	4,625	4,375	3,000	2,434	89	589	4,689	4,600	15,441	17,441	14,037	14,037	3,196	3,396	0	0	0	-	-	-	-
Proceeds from sale of equity securities
-	-	-	-	-	1,516	3,727	3,497	3,497	2,211	0	0	0	-	-	-	-	-	-	-	-	-1,331	-20,259	-20,391	-29,325	-30,556	0	0	0	-	-	-	-	-	-	-	-
Acquisition of businesses, net of cash acquired
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,683	1,683	-18,755	-20,250	-20,528	0	0	0	-	-	-	-	28,186	0	0	0
Purchase of marketable securities
-	-	-	-	-	-	-	-	0	-	-	-	-	15,644	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	25,806	28,923	47,297	55,175	100,161	0	0	0
Proceeds from the sale of property, plant and equipment
678	671	705	692	682	1,223	4,362	4,713	4,717	7,271	4,298	4,091	4,496	1,401	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital expenditures
15,435	12,741	11,901	21,498	24,817	27,858	39,286	42,511	42,960	46,524	33,593	22,486	18,272	18,547	23,439	22,273	20,295	10,846	5,221	3,706	4,236	4,734	4,906	4,375	4,068	3,962	3,399	3,118	2,052	1,472	1,768	1,819	2,020	1,953	0	0	0
Net cash used in investing activities
-14,757	-13,270	-12,396	-21,776	-25,105	-26,119	-37,191	-41,921	-45,371	-46,667	-39,192	-3,405	-17,082	-20,702	-22,160	-34,472	-108,920	-99,221	-92,083	-100,802	-5,774	-5,675	33,997	80,834	30,702	30,317	-126	-56,219	-7,546	-24,769	5,944	28,845	37,921	-14,836	0	0	0
Cash flows from financing activities:
Issuance of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	104,828	0	0	0
Issuance of 2033 Senior Notes, including to related parties
0	200,293	200,293	200,293	200,293	55,000	55,000	55,000	55,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	170,184	0	0	0	-	-	-	-	-	-	-	-
Debt issuance costs
0	7,762	7,762	7,762	7,762	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the exercise of Common Stock options and warrants
0	-3	-3	852	1,170	1,173	1,389	534	266	2,132	4,380	8,580	8,288	8,576	6,853	10,467	15,363	25,921	26,042	27,547	24,001	12,928	30,430	24,653	24,069	23,425	5,638	2,306	3,243	2,279	2,172	2,428	1,140	1,244	0	0	0
Payment of Series D dividends, including related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,015	0	0	0	-	-	-	-	-	-	-	-
Repayments under lines of credit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Cash from non-controlling interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100	2,796	2,796	3,487	2,696	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Contingent consideration payments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,435	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Borrowings on lines of credit
445,718	294,780	103,802	47,795	55,766	26,917	39,345	65,714	91,207	92,421	82,135	58,435	24,984	22,407	165,796	259,797	261,429	261,339	118,476	23,223	27,351	26,443	29,290	33,481	30,399	34,577	31,730	30,307	34,597	36,506	34,633	31,101	22,610	15,300	0	0	0
Repayments of Lines of Credit
512,018	359,322	164,723	92,581	57,574	34,681	41,302	40,909	38,413	33,510	27,920	30,362	66,346	66,178	209,712	293,674	256,855	254,355	110,090	23,820	27,233	28,369	33,114	35,850	38,031	38,997	0	0	0	-	-	-	-	-	-	-	-
Redemption of 2033 Senior Notes
0	28,800	28,800	28,800	28,800	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayments of lines of credit and capital lease obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-
Net cash (used in) provided by financing activities
9,762	175,248	195,307	212,297	255,593	140,909	54,432	80,339	108,060	61,043	58,595	36,653	-33,074	-35,195	-37,144	-23,410	19,246	33,005	37,305	29,746	27,606	7,263	17,632	15,849	7,463	183,635	170,185	163,059	170,794	6,031	-3,373	-1,745	-13,368	86,917	0	0	0
Effect of exchange rate changes on cash and cash equivalents
-821	-477	-818	-626	-572	-675	-1,513	-471	-117	470	197	-560	-1,098	-1,014	-583	-242	430	-1,117	50	-637	-1,061	-100	-76	329	154	138	217	-164	-109	-2	-103	-84	0	-81	0	0	0
Net increase (decrease) in cash and cash equivalents
-172,720	-11,021	20,949	30,734	107,307	4,974	-56,644	-50,149	-31,109	-77,234	-44,284	-25,485	-43,921	-24,865	-67,498	-65,202	-173,219	96,691	93,886	87,207	191,796	-88,891	-37,576	14,949	-25,200	158,437	132,406	80,890	134,478	-44,155	-23,807	-678	-761	53,500	0	0	0
SUPPLEMENTAL INFORMATION:
Interest paid
16,374	11,873	11,529	6,702	1,946	2,076	1,535	1,350	1,404	1,313	1,780	2,738	2,817	2,890	4,174	3,748	3,627	4,572	3,971	5,229	5,424	6,276	5,503	5,860	5,585	3,407	3,458	922	1,010	945	0	0	0	-	0	0	0
Income taxes paid, net of refunds
2,444	2,667	-2,190	-4,529	-2,680	-1,410	3,400	6,346	6,860	5,416	-29,268	-29,973	-27,779	-27,122	11,541	11,294	6,157	4,879	1,771	915	804	954	1,571	1,875	1,816	1,321	376	1,014	463	575	0	0	0	-	-	-	-
Operating lease right-of-use assets due to adoption of ASU No. 2016-02
6,103	39,380	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease liabilities due to adoption of ASU No. 2016-02
5,959	39,703	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
RXi common stock received
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,500	0	0	0	-	-	-	-	-	-	-	-
Pharmsynthez common stock received
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,264	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-
Shares issued upon the conversion of:
Shares issued upon the conversion of - 2033 Senior Notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Common Stock options and warrants, surrendered in net exercise
0	20	20	20	826	806	806	806	850	1,546	1,546	1,571	1,011	350	478	455	166	14,369	14,241	14,240	17,075	3,494	3,494	3,493	657	815	0	0	0	-	-	-	-	-	-	-	-